CFO Timothy Robert Henrichs buys 7,593 shares at $1.96; 2 other insiders bought within 14 days at unprofitable biotech
Henrichs acquired 7,593 shares at $1.96 on 2026-04-01, representing his first position in NRXS, occurring amid a cluster pattern where 2 other insiders also purchased within the past 14 days. The transaction timing coincides with sharp recent price momentum: the stock has risen 23.1% over 30 days and 62.6% over 90 days, now trading at $7.25 versus the $1.96 entry—a 270% gain from the purchase date. However, the company remains fundamentally challenged: it reported a net loss of $-2.1M over its most recent full fiscal year and continues unprofitable, despite 32.9% annual revenue growth. The multi-insider buy cluster warrants analysis of whether these purchases reflect material non-public information about a turnaround inflection, or whether they are responding to the same publicly visible momentum.